What is the share price of Hester Biosciences Ltd (HESTERBIO) today?
The share price of HESTERBIO as on 23rd April 2025 is ₹1808.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Hester Biosciences Ltd (HESTERBIO) share?
The past returns of Hester Biosciences Ltd (HESTERBIO) share are- Past 1 week: 2.89%
- Past 1 month: 27.41%
- Past 3 months: -16.76%
- Past 6 months: -20.86%
- Past 1 year: 9.03%
- Past 3 years: -30.53%
- Past 5 years: 69.16%
What are the peers or stocks similar to Hester Biosciences Ltd (HESTERBIO)?
The peers or stocks similar to Hester Biosciences Ltd (HESTERBIO) include:What is the dividend yield % of Hester Biosciences Ltd (HESTERBIO) share?
The current dividend yield of Hester Biosciences Ltd (HESTERBIO) is 0.33.What is the market cap of Hester Biosciences Ltd (HESTERBIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hester Biosciences Ltd (HESTERBIO) is ₹1532.60 Cr as of 23rd April 2025.What is the 52 week high and low of Hester Biosciences Ltd (HESTERBIO) share?
The 52-week high of Hester Biosciences Ltd (HESTERBIO) is ₹3379 and the 52-week low is ₹1242.95.What is the PE and PB ratio of Hester Biosciences Ltd (HESTERBIO) stock?
The P/E (price-to-earnings) ratio of Hester Biosciences Ltd (HESTERBIO) is 81.18. The P/B (price-to-book) ratio is 5.06.Which sector does Hester Biosciences Ltd (HESTERBIO) belong to?
Hester Biosciences Ltd (HESTERBIO) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Hester Biosciences Ltd (HESTERBIO) shares?
You can directly buy Hester Biosciences Ltd (HESTERBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Hester Biosciences Ltd
HESTERBIO Share Price
1,808.400.38% (+6.80)
HESTERBIO Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
HESTERBIO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
HESTERBIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 49.23 | 5.06 | 0.33% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.08 | 6.37 | 0.53% |
HESTERBIO Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
HESTERBIO Company Profile
Hester Biosciences Limited is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include Poultry Division and Large Animal Division.
HESTERBIO Similar Stocks (Peers)
Compare with peersBIOCON
PE Ratio
39.11
1Y Return
19.83%
Buy Reco %
73.33
ONESOURCE
PE Ratio
-44.61
1Y Return
7.84%
Buy Reco %
—
SAILIFE
PE Ratio
177.96
1Y Return
6.88%
Buy Reco %
66.67
PANACEABIO
PE Ratio
-2,744.77
1Y Return
271.43%
Buy Reco %
—
3BBLACKBIO
PE Ratio
48.00
1Y Return
141.92%
Buy Reco %
—
HESTERBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
HESTERBIO Stock Summary · February 2025
In Q3 FY25, the company faced significant challenges, including a 6% decline in divisional product sales and a 24% drop in the Animal Healthcare System, largely due to external pressures like lower milk prices and regulatory bans. However, an impressive 85% year-on-year profit increase for the first nine months was driven by operational efficiencies and foreign exchange gains. The Petcare division thrived with a 105% sales surge, reflecting strong market potential, while the Poultry Healthcare segment benefited from heightened disease awareness. Despite a dip in consolidated EBITDA, management remains optimistic about long-term growth, particularly in the Petcare sector, and is committed to innovation and strategic expansion, especially in the African market.
Key Points on Hesterbio Stock
HESTERBIO Stock Growth Drivers
7Strong Financial Performance
Hester Biosciences Limited has reported significant financial achievements, including a year-on-year profitability growth of 85%
Growth in Poultry Healthcare Division
The Poultry Healthcare division has shown strong performance, with sales increasing by 12% in Q3
HESTERBIO Stock Challenges
4Decline in Financial Performance
Hester Biosciences reported disappointing financial results, with a consolidated EBITDA of Rs. 5 crore, the
Sales Decline in Key Divisions
The Animal Healthcare System experienced a 24% decline in sales for Q3, although it maintained
HESTERBIO Forecasts
Price
Revenue
Earnings
HESTERBIO Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeHESTERBIO Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeHESTERBIO Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeHESTERBIO
Income
Balance Sheet
Cash Flow
Annual Normal View
HESTERBIO Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 101.77 | 123.53 | 138.49 | 185.28 | 189.64 | 219.01 | 249.17 | 285.65 | 319.80 | 326.72 | ||||||||||
Raw Materials | 22.53 | 29.11 | 35.39 | 41.92 | 44.15 | 46.63 | 75.41 | 82.74 | 87.14 | 250.64 | ||||||||||
| Power & Fuel Cost | 5.81 | 5.59 | 6.37 | 7.83 | 8.13 | 7.57 | 10.28 | 12.74 | 15.30 | |||||||||||
| Employee Cost | 15.44 | 18.32 | 23.24 | 28.93 | 40.65 | 38.92 | 45.33 | 56.02 | 64.13 | |||||||||||
| Selling & Administrative Expenses | 13.55 | 15.93 | 17.92 | 24.99 | 37.78 | 35.47 | 40.18 | 54.77 | 56.48 | |||||||||||
| Operating & Other expenses | 10.18 | 13.15 | 5.75 | 6.36 | -2.85 | 20.41 | 3.82 | 9.22 | 27.85 | |||||||||||
EBITDA | 34.26 | 41.43 | 49.82 | 75.25 | 61.78 | 70.01 | 74.15 | 70.16 | 68.90 | 76.08 | ||||||||||
| Depreciation/Amortization | 5.75 | 7.00 | 9.66 | 11.76 | 13.07 | 13.31 | 16.58 | 20.70 | 17.17 | 16.36 | ||||||||||
| PBIT | 28.51 | 34.43 | 40.16 | 63.49 | 48.71 | 56.70 | 57.57 | 49.46 | 51.73 | 59.72 | ||||||||||
| Interest & Other Items | 3.72 | 3.50 | 4.04 | 6.63 | 7.37 | 6.60 | 4.06 | 9.32 | 19.78 | 14.03 | ||||||||||
| PBT | 24.79 | 30.93 | 36.12 | 56.86 | 41.34 | 50.10 | 53.51 | 40.14 | 31.95 | 45.69 | ||||||||||
| Taxes & Other Items | 5.62 | 7.38 | 10.51 | 15.29 | 12.16 | 15.68 | 14.17 | 13.53 | 13.07 | 14.56 | ||||||||||
| Net Income | 19.17 | 23.55 | 25.61 | 41.57 | 29.18 | 34.42 | 39.34 | 26.61 | 18.88 | 31.13 | ||||||||||
| EPS | 22.53 | 27.68 | 30.11 | 48.87 | 34.30 | 40.46 | 46.25 | 31.28 | 22.19 | 36.59 | ||||||||||
| DPS | 4.10 | 5.30 | 10.00 | 11.00 | 6.60 | 10.00 | 10.00 | 8.00 | 6.00 | 6.00 | ||||||||||
| Payout ratio | 0.18 | 0.19 | 0.33 | 0.23 | 0.19 | 0.25 | 0.22 | 0.26 | 0.27 | 0.16 |
HESTERBIO Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFHESTERBIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Hester Biosciences Ltd | 81.18 | 5.06 | 0.33% |
| Biocon Ltd | 39.11 | 1.58 | 0.15% |
| Onesource Specialty Pharma Ltd | -44.61 | 44.10 | — |
| Sai Life Sciences Ltd | 177.96 | 15.11 | — |
HESTERBIO Stock Price Comparison
Compare HESTERBIO with any stock or ETFCompare HESTERBIO with any stock or ETF
HESTERBIO
HESTERBIO Shareholdings
HESTERBIO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
HESTERBIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
HESTERBIO Shareholding Pattern
HESTERBIO Shareholding History
Foreign Institutions
Mutual Funds Invested in HESTERBIO
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Hester Biosciences Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.04% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 97/110 (-14) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing HESTERBIO stock
Looks like this stock is not in any smallcase yet.
HESTERBIO Events
HESTERBIO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HESTERBIO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.33%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.33 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
HESTERBIO Upcoming Dividends
No upcoming dividends are available
HESTERBIO Past Dividends
Cash Dividend
Ex DateEx DateAug 22, 2024
Final
Final | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Aug 22, 2024
Cash Dividend
Ex DateEx DateSep 13, 2023
Final
Final | Div/Share: ₹8.00
Dividend/Share
₹8.00
Ex DateEx Date
Sep 13, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Final
Final | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Final
Final | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateAug 27, 2020
Final
Final | Div/Share: ₹6.60
Dividend/Share
₹6.60
Ex DateEx Date
Aug 27, 2020
HESTERBIO Stock News & Opinions
Articles & Videos
Earnings
Hester Biosciences consolidated net profit rises 192.96% in the December 2024 quarter
Net profit of Hester Biosciences rose 192.96% to Rs 11.66 crore in the quarter ended December 2024 as against Rs 3.98 crore during the previous quarter ended December 2023. Sales declined 5.61% to Rs 63.22 crore in the quarter ended December 2024 as against Rs 66.98 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales63.2266.98 -6 OPM %8.0215.15 - PBDT17.6610.16 74 PBT13.376.41 109 NP11.663.98 193 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Hester Biosciences to declare Quarterly Result
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 30 January 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Hester Biosciences receives reaffirmation in credit rating for bank facilities
Hester Biosciences has received reaffirmation in credit ratings for bank facilities at CARE BBB+; Stable / CARE A2 from CARE Ratings. Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 100.49% in the September 2024 quarter
Net profit of Hester Biosciences rose 100.49% to Rs 8.20 crore in the quarter ended September 2024 as against Rs 4.09 crore during the previous quarter ended September 2023. Sales rose 18.78% to Rs 83.69 crore in the quarter ended September 2024 as against Rs 70.46 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales83.6970.46 19 OPM %22.8918.75 - PBDT16.0711.05 45 PBT11.876.76 76 NP8.204.09 100 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Hester Biosciences announces board meeting date
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 8.01% in the June 2024 quarter
Net profit of Hester Biosciences rose 8.01% to Rs 6.34 crore in the quarter ended June 2024 as against Rs 5.87 crore during the previous quarter ended June 2023. Sales declined 6.35% to Rs 82.27 crore in the quarter ended June 2024 as against Rs 87.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales82.2787.85 -6 OPM %21.4516.35 - PBDT14.7314.31 3 PBT10.598.91 19 NP6.345.87 8 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Hester Biosciences to hold AGM
Hester Biosciences announced that the Annual General Meeting (AGM) of the company will be held on 29 August 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Hester Biosciences schedules board meeting
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Hester Biosciences Ltd leads gainers in ‘B’ group
10 months agoBusiness Standard
Hester Biosciences to repurpose BSL-3 facility as Covid vaccine demand tapers off
1 year agoThe Hindu Businessline
Over the last 5 years, revenue has grown at a yearly rate of 11.53%, vs industry avg of 19.04%
Over the last 5 years, market share decreased from 2.42% to 1.73%
Over the last 5 years, net income has grown at a yearly rate of -14.6%, vs industry avg of 2.04%